Biotech Job Trends: Week Ending May 4, 2026

Welcome back to Biotech Job Trends, Company Canary's weekly snapshot of hiring activity across the biotech and biopharma companies our users follow. After two consecutive weeks of rapid coverage expansion (28 new companies added between them), this week is structurally different: zero new companies entered the tracker. That sounds like a quiet week — but it's actually the most informative week we've had so far, because for the first time we can read hiring momentum cleanly, without new-to-coverage jobs inflating the numbers.

A reminder on scope: the companies below reflect what Company Canary users have asked us to track, not a full biotech index. Coverage is broadening over time, but for now, treat this as a directional signal rather than a representative survey of the whole industry. We've also excluded a handful of very large employers (Sanofi, Pfizer, Eli Lilly, Amgen, AstraZeneca) along with two non-biotech trackers (Doximity, Zanskar) so the view isn't dominated by a few mega-cap posting volumes.

As of Monday, May 4, 2026:

Net change vs. last week: −60 active jobs and 0 companies. This is the first net-decline week since we started tracking — and the story underneath that small number is worth unpacking.

Zero. For the first time in this series, no new companies entered the Company Canary tracker over the past seven days.

That's not a problem — it's an opportunity. The first two weeks of this series were dominated by coverage expansion: nine new companies in week one, nineteen in week two, almost all of them entering with healthy backlogs of existing job postings. That made the topline numbers grow fast, but it also made it hard to separate "real new hiring" from "new to our coverage." This week, with the tracker stable at 56 active companies, every single job movement is genuine activity at companies already in the database. That makes the rest of this post the cleanest hiring-momentum read we've published.

Here's the headline data point: 417 new job postings appeared this week, and 438 were closed. Net active jobs declined by 60. About 15% of last week's active pool turned over in seven days.

That's not a contraction story — it's a turnover story. Biopharma is a high-churn hiring environment. Roles get posted, filled, expire, or get pulled and re-posted under different titles. Until this week, that churn was hidden inside our growing denominator. Now it's visible.

Three roles worth a look

Three postings stood out as cleaner reads on where specific companies are investing:

1. Tempus AI — six new "MRD Clinical Account Executive" roles in Indiana, Wisconsin, Cleveland/Pittsburgh, Orange County, DC/MD/VA, and Tennessee/Kentucky. MRD (minimal residual disease) testing is one of Tempus's commercial growth bets in oncology — and posting six geographically distributed field roles in a single week is an unmistakable scale-out signal. Tempus's hiring activity more than doubled overall this week (from 9 to 19 new postings), almost entirely on the commercial side.
2. Regeneron — Senior Director, AI Strategy & Operations (Sleepy Hollow, NY), paired with a Senior Manager, Artificial Intelligence in Global Development and a Director, Data Enablement. Three AI and data leadership roles posted in one week at one of the most established traditional biotechs in our tracker. Last week's AI story was platform companies entering coverage; this week's AI story is established companies building AI strategy functions internally. Different flavor, same direction.
3. Natera — Senior Product Manager, Chat AI & Automation (US Remote). A genetic testing company hiring a dedicated PM for conversational AI in customer experience. This kind of role barely existed at diagnostics companies two years ago — it's a small but interesting marker of how operational AI is becoming a first-class function across biotech adjacencies, not just at AI-first drug discovery shops.

Where the volume is coming from

A handful of companies did most of this week's gross hiring activity:

• Regeneron — 66 new postings (still the broadest hirer, down from 78 last week). Notably, Regeneron also closed 68 roles this week — the highest two-way churn in the dataset. The functional mix continues to tilt heavily toward IT/Oracle systems work, manufacturing, and field commercial.
• Biogen — 40 new postings (up from 32). Continued investment in regulated commercial infrastructure: Head of Advertising/Labeling/Promotion, Head of Market Access for Australia/New Zealand, Head of Patient Services Strategic Planning. Three "Head of" hires in a single week is unusual and worth noting.
• Revolution Medicines — 39 new postings (up from 31), but with 53 closures — net −14 active roles. The closures are notable: Director of Global Marketing, multiple Senior Directors in Regulatory Affairs and HEOR, Executive Medical Director for GI in Europe. These are senior commercial and regulatory roles, the kind a company posts during pre-launch buildout. The fact that they're closing now could mean the roles were filled (likely), or that the company is recalibrating its launch infrastructure. Worth watching over the next few weeks.
• Natera — 37 new postings, Exact Sciences — 27, Vertex Pharmaceuticals — 24, Illumina — 20.

Net winners and net losers this week

Because hiring and closures both ran hot this week, the more interesting view is net change in active postings by company:

Net positive	Net change
Structure Therapeutics	+10
Cytokinetics	+8
Telix Pharmaceuticals	+8
Tempus AI	+7
Formation Bio	+6
10x Genomics	+3
Iovance Biotherapeutics	+3

Net negative	Net change
Legend Biotech	−17
Revolution Medicines	−14
Regeneron	−10
Argenx	−9
Vertex Pharmaceuticals	−6
Twist Bioscience	−6
Exact Sciences	−5
Kailera	−5

A few things worth calling out:

• Legend Biotech (−17) looks largely seasonal. The closures are heavy on internships, co-ops, and early-career program roles — the kind that naturally roll off as academic terms end. Less a hiring slowdown, more a calendar artifact.
• Argenx (−9) is more interesting. The closures are concentrated in international field-team roles: Brazil medical science liaisons, Italy key account manager, Quebec market access lead, US patient advocacy. Reads as a deliberate consolidation of the field organization, particularly in LATAM and Europe.
• Structure Therapeutics (+10) continues building since being added to the tracker last week. They're now the largest single-week net adder in the dataset.

Seniority skew of this week's new roles

Across the 417 new postings, the seniority mix is more director-heavy than the previous two weeks:

Level	Share of new roles
Individual Contributor	25.9%
Director	11.3%
Senior (IC)	11.3%
Manager	10.8%
Associate Director	10.6%
Senior Director	7.9%
Principal / Staff / Lead	7.4%
Other	7.2%
Senior Manager	4.3%
Intern / Trainee	1.7%
Executive Director	1.4%
VP+	0.2%

Director-and-above climbed to 31.2% of new postings this week, up from ~22% last week. IC + Senior IC dropped from ~41% to ~37%. The shape of the week's hiring suggests companies were filling specific senior gaps rather than scaling out execution capacity — consistent with a churn-heavy week where filled roles need to be backfilled at the same level.

Zooming out from the week to the full set of 2,906 active postings:

Seniority

The current active pool stayed broadly similar in shape to last week:

• ~32% director-and-above (Associate Director through VP+)
• ~17% manager-level (Manager + Senior Manager)
• ~10% principal / staff / lead
• ~32% IC / senior IC
• ~3% intern or trainee roles

Director-and-above is up about a percentage point from last week — consistent with this week's senior-skewed inflow.

Geography

Notably, the geographic distribution barely moved this week:

Region	This week	Last week
Boston / Cambridge MA	15.8%	15.7%
SF Bay Area	12.6%	12.5%
Remote	11.3%	11.3%
NY / NJ metro	9.6%	9.7%
San Diego CA	6.7%	6.6%
Europe / UK	5.0%	4.8%
Asia-Pacific	4.5%	4.2%
Madison WI	2.1%	2.1%
Research Triangle NC	1.5%	1.6%

No metro shifted by more than 0.3 percentage points. That stability is itself a useful baseline: when no new companies enter the tracker, geographic distribution is essentially conserved, even with hundreds of jobs flowing in and out. Which means the dramatic Bay Area jump we saw last week (9.6% → 12.5%) really was driven by who entered coverage, not by an underlying geographic shift in biotech hiring.

Function

Function	Share	vs. last week
Other / uncategorized	24.0%	+0.4 pp
Clinical & Medical	16.6%	−0.1 pp
Commercial & Marketing	13.1%	−1.1 pp
Manufacturing & Operations	11.5%	−0.5 pp
Data, IT & Digital	10.1%	+0.4 pp
Regulatory & Quality	8.7%	+0.3 pp
Research & Discovery	7.5%	+0.1 pp
Finance & Legal	3.5%	+0.0 pp
Engineering (other)	2.2%	+0.1 pp
People & Admin	1.7%	+0.3 pp
Project / Program Mgmt	1.0%	+0.0 pp

The one notable shift: Commercial & Marketing dropped 1.1 percentage points (from 14.2% to 13.1%). That's not a huge move, but it's directionally consistent with the closures we saw at Revolution Medicines (commercial leadership) and Argenx (international field teams) — both pulled meaningful commercial headcount out of the active pool this week. Worth tracking whether that direction holds next week.

Data, IT & Digital, by contrast, continued to climb — now at 10.1% of all active postings, up from 6.8% three weeks ago. That trend has been one-directional across all three weeks.

• All figures reflect the state of the Company Canary database as of Monday, May 4, 2026.
• The dataset excludes seven companies for this post: Sanofi, Pfizer, Eli Lilly, Amgen, AstraZeneca (whose posting volumes would dominate the numbers), and two non-biotech entries (Doximity, Zanskar).
• Coverage is driven by what Company Canary users choose to track. It is not a representative sample of the biotech industry as a whole, and it tilts toward publicly-traded companies and well-known private ones. New companies are added over time, so the denominator will continue to evolve.
• A reminder on the "new to coverage vs. truly new" distinction: when a new company enters the tracker, its currently-open roles enter the database simultaneously and get a fresh first_seen_at timestamp. Those aren't truly fresh postings — they're new to our coverage. This week, with zero new companies, every "new this week" job is genuinely freshly posted, which is why the numbers are unusually clean to interpret.
• A note on "closures": when our daily reconciliation detects that a job is no longer present on the company's careers page, we mark it inactive. The reasons are mixed — filled, expired, paused, re-posted under a new title — and we don't always know which. So "X closures" should be read as "X postings disappeared," not "X people were hired."
• Seniority and function classifications are derived from job titles using pattern matching, so they're directional rather than exact. Geography is normalized from raw location strings and rolled up into metros or regions.

See you next Monday.